Decades late, these set of basic rules for Indian pharma can save lives
Related Posts
Can Cipla make inhaled insulin a successful option for diabetes patients?
Umang Vohra, Global CEO, Cipla. Will Cipla’s big bet work?; image credit: Company. Synopsis Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing Afrezza, an inhaled insulin, in India. Will doctors and patients buy this option? A blue travel case of insulin injections is […]
India pharma industry: From whistleblower, Dinesh Thakur’s long road to reforming India’s pharma industry
His name splits the Indian drug industry down the middle. Dinesh Thakur is either admired for his tireless zeal to bring about reform in India’s drug-regulatory system, or tempers flare up at the mention of his name. His motives are often questioned for chasing an “agenda” to malign drugmakers of India, which prides itself on […]
usfda: Closer USFDA lens will keep Indian pharma edgy, but companies now better placed to handle the glare
Three months ago, Robert M Califf, commissioner of the US Food and Drug Administration (USFDA) visited India to strengthen efforts on development, supply, and quality of drugs. For the US, where more than nine out of 10 prescriptions dispensed are generic drugs, India is a critical partner, responsible for supplying a substantial portion of these […]